ArticleScientific reports2020
Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis.Nature communications · 2026Pooled it
- Detection rates for prostate cancer using PI-RADS 2.1 upgrading rules in transition zone lesions align with risk assessment categories: a systematic review and meta-analysis.European radiology · 2025Pooled it
- Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.The British journal of radiology · 2022Pooled it
- Interobserver Agreement and Accuracy in Interpreting mpMRI of the Prostate: a Systematic Review.Current urology reports · 2022Pooled it
- An Assessment of PI-RADS v2.1: Inter-Reader Agreement, Diagnostic Accuracy, and the Added Value of PSA Density in Prostate Cancer Prediction.Diagnostics (Basel, Switzerland) · 2026Article
- Polygenic risk scores for premagnetic resonance imaging risk stratification in men with clinically suspected prostate cancer.Journal of the National Cancer Institute · 2026Article
- Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision.Insights into imaging · 2026Article
- Structured reporting of B-mode, color Doppler, and CEUS in testicular tumor assessment: a reader study with urologist ratings.BMC urology · 2026Article
- A multi-center study: development and validation of a BpMRI focused model in transition zone PI-RADS 3 and 4 lesions to detect clinically significant prostate cancer.Abdominal radiology (New York) · 2025Article
- Combination of PI-RADS version 2.1 and amide proton transfer values for the detection of clinically significant prostate cancer.BMC cancer · 2025Article
- Clinical and Imaging Predictors of False-Positive and False-Negative Results in Prostate Multiparametric MRI Using PI-RADS Version 2.Radiology. Imaging cancer · 2025Article
- Review
- Enhancing Prostate Cancer Detection Accuracy in Magnetic Resonance Imaging-targeted Prostate Biopsy: Optimizing the Number of Cores Taken.European urology open science · 2024Review
- MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed.Prostate cancer and prostatic diseases · 2023Article
- Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.Radiology · 2023Article
- Characterization of high-grade prostate cancer at multiparametric MRI: assessment of PI-RADS version 2.1 and version 2 descriptors across 21 readers with varying experience (MULTI study).Insights into imaging · 2023Article
- [Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points].Journal of the Korean Society of Radiology · 2023Review
- The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP).Current oncology (Toronto, Ont.) · 2022Article
- Quantib Prostate Compared to an Expert Radiologist for the Diagnosis of Prostate Cancer on mpMRI: A Single-Center Preliminary Study.Tomography (Ann Arbor, Mich.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study is to compare diagnostic performance of Prostate Imaging Reporting and Data System (PI-RADS) version (v) 2.1 and 2.0 for detection of Gleason Score (GS) ≥ 7 prostate cancer on MRI. Three experienced radiologists provided PI-RADS v2.0 scores and at least 12 months later v2.1 scores on lesions in 333 prostate MRI examinations acquired between 2012 and 2015. Diagnostic performance was assessed retrospectively by using MRI/transrectal ultrasound fusion biopsy and 10-core systematic biopsy as the reference. From a total of 359 lesions, GS ≥ 7 tumor was present in 135 lesions (37.60%). Area under the ROC curve (AUC) revealed slightly lower values for peripheral zone (PZ) and transition zone (TZ) scoring in v2.1, but these differences did not reach statistical significance. A significant number of score 2 lesions in the TZ were downgraded to score 1 in v2.1 showing 0% GS ≥ 7 tumor (0/11). The newly introduced diffusion-weighted imaging (DWI) upgrading rule in v2.1 was applied in 6 lesions from a total of 143 TZ lesions (4.2%). In summary, PI-RADS v2.1 showed no statistically significant differences in overall diagnostic performance of TZ and PZ scoring compared to v2.0. Downgraded BPH nodules showed favorable cancer frequencies. The new DWI upgrading rule for TZ lesions was applied in only few cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.